Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schülin, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schülin, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 403-406
© 2002 The British Society for Antimicrobial Chemotherapy

Brief report

In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany

Tanja Schülin,*

Department of Microbiology and Hygiene, University of Freiburg, Freiburg, Germany

Three hundred and eighty-five mucoid and non-mucoid strains of Pseudomonas aeruginosa isolated from 192 sputa from 57 adult cystic fibrosis patients were studied. Susceptibility testing using an agar dilution technique was performed for ceftazidime, ciprofloxacin, fosfomycin, meropenem and piperacillin, and the aerosolized agents colistin and tobramycin. Meropenem, ceftazidime and piperacillin were the most potent agents (susceptibility 86.2%, 84.2% and 84%, respectively). Tobramycin and colistin susceptibility rates were lower, but in light of higher intrabronchial concentrations of these drugs a greater percentage of strains might still be clinically susceptible. Only 46.2% and 41.8% of isolates were susceptible to ciprofloxacin and fosfomycin, respectively.

* Correspondence address. UMC St Radboud, University of Nijmegen, Department of Clinical Microbiology, MMB 440, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Tel: +31-24-361-9560; Fax: +31-24-3540216; E-mail: T.Schulin{at}mmb.azn.nl


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
D. L. MacLeod, L. M. Barker, J. L. Sutherland, S. C. Moss, J. L. Gurgel, T. F. Kenney, J. L. Burns, and W. R. Baker
Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis
J. Antimicrob. Chemother., October 1, 2009; 64(4): 829 - 836.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Sun, A. Negrea, M. Rhen, and D. I. Andersson
Genetic Analysis of Colistin Resistance in Salmonella enterica Serovar Typhimurium
Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2298 - 2305.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
N. Aoki, K. Tateda, Y. Kikuchi, S. Kimura, C. Miyazaki, Y. Ishii, Y. Tanabe, F. Gejyo, and K. Yamaguchi
Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa
J. Antimicrob. Chemother., March 1, 2009; 63(3): 534 - 542.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
D. Landman, C. Georgescu, D. A. Martin, and J. Quale
Polymyxins Revisited
Clin. Microbiol. Rev., July 1, 2008; 21(3): 449 - 465.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. B. Bulitta, S. B. Duffull, M. Kinzig-Schippers, U. Holzgrabe, U. Stephan, G. L. Drusano, and F. Sorgel
Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers
Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2497 - 2507.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
D. Hill, B. Rose, A. Pajkos, M. Robinson, P. Bye, S. Bell, M. Elkins, B. Thompson, C. MacLeod, S. D. Aaron, et al.
Antibiotic Susceptibilities of Pseudomonas aeruginosa Isolates Derived from Patients with Cystic Fibrosis under Aerobic, Anaerobic, and Biofilm Conditions
J. Clin. Microbiol., October 1, 2005; 43(10): 5085 - 5090.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
M. I. Morosini, M. Garcia-Castillo, E. Loza, M. Perez-Vazquez, F. Baquero, and R. Canton
Breakpoints for Predicting Pseudomonas aeruginosa Susceptibility to Inhaled Tobramycin in Cystic Fibrosis Patients: Use of High-Range Etest Strips
J. Clin. Microbiol., September 1, 2005; 43(9): 4480 - 4485.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. Poole
Aminoglycoside Resistance in Pseudomonas aeruginosa
Antimicrob. Agents Chemother., February 1, 2005; 49(2): 479 - 487.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Hogardt, S. Schmoldt, M. Gotzfried, K. Adler, and J. Heesemann
Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients
J. Antimicrob. Chemother., December 1, 2004; 54(6): 1057 - 1061.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
T L Pitt, M Sparrow, M Warner, and M Stefanidou
Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents
Thorax, September 1, 2003; 58(9): 794 - 796.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.